Outsourcing

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

Articles

CMO industry consolidation may be frustrated by a dearth of attractive assets.

CMO Investors Have More Money Than Places to Spend It

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Better process development is creating industry benchmarks for bioprocessing.

CMOs Continue to Improve Overall Biomanufacturing Performance

While biologics development grabs investor interest, small-molecule APIs still hold two-thirds of the drug-development pipeline.

CMOs Ride Continuing Strength of Small-Molecule Drug Sector

Despite emergence of biologics, small-molecule APIs benefit from industry growth.

Small-Molecule API CMOs Are Thriving

Suppliers indicate prices for single-use equipment are likely to increase.

CMOs Concerned With Cost of Single-Use Equipment

Biopharma companies are outsourcing more jobs to cut costs.

Outsourcing Becoming More Cost Competitive

While all market signs are pointing up, memories of past setbacks may discourage from expanding capacity.

CDMOs Cautiously Address Expansion

Biopharma companies on both sides of the Atlantic ship more of their assay testing to outside service providers.

Another In-House Operation Gets Outsourced

While the United States and Europe still dominate, CMOs and CROs based in emerging markets continue to capture market share.

Biomanufacturing Outsourcing Globalization Continues

Big service providers get bigger faster thanks to Big Pharma.

Outsourcing Outlook